Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protagonist Therapeutics (PTGX) Depreciation & Amortization (CF): 2014-2024

Historic Depreciation & Amortization (CF) for Protagonist Therapeutics (PTGX) over the last 11 years, with Dec 2024 value amounting to $826,000.

  • Protagonist Therapeutics' Depreciation & Amortization (CF) rose 56.28% to $361,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.0 million, marking a year-over-year increase of 6.90%. This contributed to the annual value of $826,000 for FY2024, which is 15.46% down from last year.
  • According to the latest figures from FY2024, Protagonist Therapeutics' Depreciation & Amortization (CF) is $826,000, which was down 15.46% from $977,000 recorded in FY2023.
  • In the past 5 years, Protagonist Therapeutics' Depreciation & Amortization (CF) ranged from a high of $1.0 million in FY2022 and a low of $813,000 during FY2021.
  • Its 3-year average for Depreciation & Amortization (CF) is $945,667, with a median of $977,000 in 2023.
  • As far as peak fluctuations go, Protagonist Therapeutics' Depreciation & Amortization (CF) grew by 29.51% in 2020, and later dropped by 15.46% in 2024.
  • Protagonist Therapeutics' Depreciation & Amortization (CF) (Yearly) stood at $948,000 in 2020, then decreased by 14.24% to $813,000 in 2021, then grew by 27.18% to $1.0 million in 2022, then declined by 5.51% to $977,000 in 2023, then decreased by 15.46% to $826,000 in 2024.